Guangzhou Wondfo Biotech 万孚生物
21 significant filings since 31 May 2026: 13 on equity incentive, 4 on buyback and 3 on major holder buying, and 1 other kind. The latest, on 17 Sep 2026: 关于2026年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告.
自 31 May 2026 起有 21 份重大公告：equity incentive 13 份、buyback 4 份、major holder buying 3 份，另有 1 类。最新一份（17 Sep 2026）：关于2026年限制性股票激励计划内幕信息知情人及激励对象买卖公司股票情况的自查报告。
As of 25 Sep 2026 截至2026年9月25日
Guangzhou Wondfo Biotech 万孚生物 is a medical devices company listed on the Shenzhen Stock Exchange since 30 Jun 2015. The company reported a net loss in 2025, with attributable net profit at -RMB63.0m, down from a profit of RMB561.6m in 2024. Revenue declined by 31.9% to RMB2.09bn. Despite the loss, operating cash flow per share improved to RMB0.99 from RMB0.75. In the first half of 2026, the company reported a profit of RMB122.5m, though this was 35.2% lower than the same period a year earlier. Liquidity remains strong, with a current ratio of 3.32 and low leverage at a liabilities to assets ratio of 18.3%. The stock has declined 22.9% over one year, and the P/E is not meaningful due to the recent loss.
万孚生物是一家医疗器械公司，于2015年6月30日在深圳证券交易所上市。2025年公司归母净利润为-6,302.5万元，由2024年盈利5.62亿元转为亏损，营业收入同比下降31.9%至20.87亿元。尽管亏损，每股经营现金流由0.75元提升至0.99元。截至2026年6月30日的上半年，公司实现归母净利润1.23亿元，同比下降35.2%。公司流动性良好，流动比率为3.32，资产负债率为18.3%。过去一年股价下跌22.9%，因亏损市盈率不适用。
| Flag 标记 | Risk 风险 | Mechanism 影响机制 |
|---|---|---|
| Attributable net loss in 2025; a profit in the period to 30 Jun 2026, -35.2% on the same period a year earlier 2025年归母净利润亏损；截至2026年6月30日的报告期盈利，较上年同期-35.2% | The company reported a net loss in 2025 and a lower profit in the first half of 2026. 公司2025年出现净亏损，2026年上半年利润同比下降。 | A shift from profit to loss in 2025 indicates weakened earnings performance. Although profitability returned in the first half of 2026, the 35.2% decline suggests ongoing pressure on earnings. This trend could affect investor confidence and future valuation. 2025年由盈转亏显示盈利表现减弱。尽管2026年上半年恢复盈利，但同比下降35.2%，表明盈利仍面临压力。此趋势可能影响投资者信心和未来估值。 |
| Revenue down 20% or more on the year before 营业收入同比下降20%或以上 | Revenue declined by more than 20% year-on-year in 2025. 2025年营业收入同比下滑超20%。 | Revenue fell from RMB3.06bn in 2024 to RMB2.09bn in 2025, a drop of 31.9%. Such a significant decline may reflect weakening demand, competitive pressures, or operational challenges, which could impair the company's ability to sustain margins and invest in growth. 营业收入从2024年的30.65亿元降至2025年的20.87亿元，下降31.9%。大幅下滑可能反映需求减弱、竞争压力或经营困难，影响公司维持利润率和投资增长的能力。 |
- Change in attributable net profit for the full year 2026 compared to 2025.
2026全年归母净利润较2025年的变动情况。 - Revenue trend in the full year 2026 versus 2025.
2026全年营业收入与2025年的变化趋势。 - Operating cash flow per share in the full year 2026.
2026全年每股经营现金流。 - Net profit excluding non-recurring items in 2026.
2026年扣除非经常性损益后的净利润。 - Liabilities to assets ratio at the end of 2026.
2026年末资产负债率。 - Gross margin level in the full year 2026.
2026全年毛利率水平。
- Company: Guangzhou Wondfo Biotech 万孚生物, Shenzhen Stock Exchange 300482; industry Medical Devices; listed 30 Jun 2015.
公司：万孚生物，深圳证券交易所 300482；行业：医疗器械；上市日期：2015年6月30日。 - Close on 24 Sep 2026 RMB16.41; close on 24 Sep 2025 RMB21.54, RMB21.27 in today's terms; one-year change, adjusted for distributions and share changes -22.9%.
2026年9月24日收盘价16.41元；2025年9月24日收盘价21.54元（前复权21.27元）；一年涨跌幅（复权）-22.9%。 - 52-week range in today's terms, adjusted for distributions and share changes RMB15.55 to RMB25.25.
52周区间（前复权）15.55元至25.25元。 - In the last 12 months 4 trading days closed 9% or more above or below the day before (all days, not only this year). The 4 most recent of them: 26 Jan 2026 +16.2%; 5 Jun 2026 +15.1%; 9 Jun 2026 +15.5%; 16 Jun 2026 +9.5%. No two of the 4 fell on consecutive trading days.
近12个月共有4个交易日收盘涨跌幅达9%及以上（为全部交易日，不限于今年）。其中最近4个：2026年1月26日 +16.2%；2026年6月5日 +15.1%；2026年6月9日 +15.5%；2026年6月16日 +9.5%。其中任意两个交易日均不相邻。 - Market capitalisation RMB7.68bn; P/E TTM not meaningful (loss-making); price to book 1.44x.
总市值76.82亿元；市盈率（TTM）不适用（亏损）；市净率1.44倍。 - Revenue 2025 RMB2.09bn; 2024 RMB3.06bn; change -31.9%.
营业收入2025年20.87亿元；2024年30.65亿元；同比-31.9%。 - Attributable net profit 2025 -RMB63.0m; 2024 RMB561.6m; change -111.2% (from a profit to a loss).
归属于母公司股东的净利润2025年-6,302.5万元；2024年5.62亿元；同比-111.2%（由盈转亏）。 - Net profit excluding non-recurring items, 2025 change -102.6%.
2025年扣除非经常性损益后的净利润同比-102.6%。 - Basic EPS 2025 -RMB0.13; 2024 RMB1.21.
基本每股收益2025年-0.13元；2024年1.21元。 - Operating cash flow per share 2025 RMB0.99; 2024 RMB0.75.
每股经营现金流2025年0.99元；2024年0.75元。 - 2025 gross margin 57.0%; net margin -3.3%; ROE -1.1%.
2025年毛利率57.0%；净利率-3.3%；净资产收益率-1.1%。 - At 30 Jun 2026: liabilities to assets 18.3%; current ratio 3.32; quick ratio 3.03; receivable days 127; inventory days 144.
截至2026年6月30日：资产负债率18.3%；流动比率3.32；速动比率3.03；应收账款周转天数127；存货周转天数144。 - Period to 30 Jun 2026 (six months, not comparable with the full years above): revenue RMB1.04bn, change -16.6%; attributable net profit RMB122.5m, change -35.2%; operating cash flow per share RMB0.91.
截至2026年6月30日的报告期（六个月，不可与上述全年数据直接比较）：营业收入10.39亿元，同比-16.6%；归母净利润1.23亿元，同比-35.2%；每股经营现金流0.91元。 - Ownership: actual controller 李文美,王继华; largest holder at 27 Jul 2026: 李文美, 20.90%.
股权：实际控制人：李文美,王继华；2026年7月27日第一大股东：李文美，持股20.90%。 - Latest distribution: ex-date 2 Jun 2026, cash RMB0.22 per share.
最近一次分配：除权除息日2026年6月2日，每股现金0.22元。 - Aurelian Grade C, score 55.5 of 100, graded within a peer group of 140 companies in its industry; no rank among peers is given.
金源评级C，得分55.5（满分100），于行业同业140家中评定；未提供其在同业中的排名。 - Not held for this report: receivable ageing, litigation case amounts, the order book, the auditor's opinion and key audit matters, segment revenue.
本报告未掌握：应收账款账龄、诉讼案件金额、在手订单、审计意见及关键审计事项、分部收入。